NZ518256A - Modified peptides and peptidomimetics for use in immunotherapy - Google Patents

Modified peptides and peptidomimetics for use in immunotherapy

Info

Publication number
NZ518256A
NZ518256A NZ518256A NZ51825600A NZ518256A NZ 518256 A NZ518256 A NZ 518256A NZ 518256 A NZ518256 A NZ 518256A NZ 51825600 A NZ51825600 A NZ 51825600A NZ 518256 A NZ518256 A NZ 518256A
Authority
NZ
New Zealand
Prior art keywords
ser
thr
gly
ala
phe
Prior art date
Application number
NZ518256A
Other languages
English (en)
Inventor
Cornelis Marius Timmers
Galen Philippus Johannes M Van
Anna Maria Helena Boots
Staveren Catherina Joanna Van
Rnaldus Marcellus Alph Knegtel
Andreas Martinus Ma Miltenburg
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Publication of NZ518256A publication Critical patent/NZ518256A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0008Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Rehabilitation Therapy (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ518256A 1999-10-18 2000-10-12 Modified peptides and peptidomimetics for use in immunotherapy NZ518256A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99203427 1999-10-18
PCT/EP2000/010230 WO2001029081A1 (en) 1999-10-18 2000-10-12 Modified peptides and peptidomimetics for use in immunotherapy

Publications (1)

Publication Number Publication Date
NZ518256A true NZ518256A (en) 2004-01-30

Family

ID=8240756

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ518256A NZ518256A (en) 1999-10-18 2000-10-12 Modified peptides and peptidomimetics for use in immunotherapy

Country Status (23)

Country Link
EP (1) EP1226167A1 (tr)
JP (1) JP2003512388A (tr)
KR (1) KR20020047245A (tr)
CN (1) CN1379786A (tr)
AR (1) AR026068A1 (tr)
AU (1) AU780238B2 (tr)
BR (1) BR0014803A (tr)
CA (1) CA2386398A1 (tr)
CO (1) CO5271650A1 (tr)
CZ (1) CZ20021356A3 (tr)
HK (1) HK1046693A1 (tr)
HU (1) HUP0203504A3 (tr)
IL (1) IL148778A0 (tr)
MX (1) MXPA02003520A (tr)
NO (1) NO20021763L (tr)
NZ (1) NZ518256A (tr)
PE (1) PE20010692A1 (tr)
PL (1) PL354590A1 (tr)
RU (1) RU2002113107A (tr)
SK (1) SK6842002A3 (tr)
TR (1) TR200201036T2 (tr)
WO (1) WO2001029081A1 (tr)
ZA (1) ZA200202577B (tr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002951212A0 (en) * 2002-09-04 2002-09-19 Monash University A method of modulating cellular activity and molecules for use therein
EP2016054A2 (en) * 2006-04-06 2009-01-21 Purdue Research Foundation Derivatization-enhanced analysis of amino acids and peptides
WO2008078190A2 (en) * 2006-12-21 2008-07-03 Universite De Geneve Compounds for fluorescence imaging
US8697384B2 (en) 2008-01-23 2014-04-15 Herlev Hospital YKL-40 as a general marker for non-specific disease
US8580520B2 (en) 2008-09-15 2013-11-12 Herlev Hospital YKL-40 as a marker for gastrointestinal cancers
EP3215172B1 (en) 2014-11-07 2023-04-26 Kineta Chronic Pain, Llc. Modifications and uses of conotoxin peptides
EP3466963A1 (en) * 2017-10-05 2019-04-10 Suigeneris Farmacosmetics, S.L. Anticancer peptides and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL115744A (en) * 1994-10-27 2000-07-16 Akzo Nobel Nv Peptides comprising a subsequence of human cartilage glycoprotein - 39
TW575583B (en) * 1996-04-24 2004-02-11 Akzo Nobel Nv Novel peptides suitable for use in antigen specific immunosuppressive therapy
DE69731747T2 (de) * 1996-06-07 2006-02-02 Astrazeneca Ab Peptid derivate
IL122233A (en) * 1996-12-06 2001-04-30 Akzo Nobel Nv Method of generating monoclonal antibodies to cell wall and pharmaceutical preparations and diagnostic agents containing them

Also Published As

Publication number Publication date
HK1046693A1 (zh) 2003-01-24
AU1139601A (en) 2001-04-30
IL148778A0 (en) 2002-09-12
MXPA02003520A (es) 2002-08-20
AR026068A1 (es) 2002-12-26
EP1226167A1 (en) 2002-07-31
JP2003512388A (ja) 2003-04-02
HUP0203504A3 (en) 2005-03-29
NO20021763D0 (no) 2002-04-15
PE20010692A1 (es) 2001-07-06
SK6842002A3 (en) 2002-09-10
TR200201036T2 (tr) 2002-08-21
PL354590A1 (en) 2004-01-26
AU780238B2 (en) 2005-03-10
RU2002113107A (ru) 2004-01-10
NO20021763L (no) 2002-04-15
CO5271650A1 (es) 2003-04-30
CA2386398A1 (en) 2001-04-26
WO2001029081A1 (en) 2001-04-26
CN1379786A (zh) 2002-11-13
BR0014803A (pt) 2002-06-11
HUP0203504A2 (hu) 2003-04-28
CZ20021356A3 (cs) 2002-07-17
KR20020047245A (ko) 2002-06-21
ZA200202577B (en) 2003-09-23

Similar Documents

Publication Publication Date Title
AU2001275930B2 (en) Alpha-msh related compounds and methods of use
AU2001275930A1 (en) Alpha-msh related compounds and methods of use
US6821517B1 (en) Compositions and methods for enhancing immune responses mediated by antigen-presenting cells
Myers et al. A synthetic peptide analogue of a determinant of type II collagen prevents the onset of collagen-induced arthritis.
US20070161545A1 (en) Triple polypeptide complexes
JPH09507861A (ja) 自己免疫疾患の免疫療法に用いるための、自己抗原から誘導された新規なペプチド
AU2003213140A1 (en) Compositions and compounds for use as molecular adjuvant for a nicotine vaccine
JP3468528B2 (ja) ペプチド誘導体
US7122193B1 (en) Retro peptides, antibodies thereto and their uses for vaccination and in vitro diagnosis
AU780238B2 (en) Modified peptides and peptidomimetics for use in immunotherapy
Sakarellos-Daitsiotis et al. Artificial carriers: a strategy for constructing antigenic/immunogenic conjugates
CA2223714A1 (en) Vaccination with peptide of mhc class ii molecules for treatment of autoimmune disease
AU2002339227A1 (en) Triple polypeptide complexes
JPH10259198A (ja) 連結したt細胞エピトープとその用途
US6423315B1 (en) Synthetic peptide for treatment of autoimmune arthritis
NZ336745A (en) A method of treating an animal with an autoimmune condition such as rheumatoid arthritis and relapsing polychrondritis
JP2002521388A (ja) 自己免疫疾患の免疫療法に使用するための新規ペプチド
Skarlas et al. HLA‐DQ7 β1 and β2 derived peptides as immunomodulators
AU4863900A (en) Vaccination with peptide of MHC class II molecules for treatment of autoimmune disease

Legal Events

Date Code Title Description
PSEA Patent sealed